2BA Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group

Publication date: February 2017
Source:European Journal of Cancer, Volume 72, Supplement 1
Author(s): J.J.M. Kwakman, L.H.J. Simkens, J.M. Van Rooijen, A.J. Van de Wouw, O.J.L. Loosveld, G.J.M. Creemers, M.P. Hendriks, M. Los, R.J. Van Alphen, M.B. Polée, E.W. Muller, A.M.T. Van der Velden, T. Van Voorthuizen, M. Koopman, L. Mol, E. Van Werkhoven, C.J.A. Punt




http://ift.tt/2k0Fh1V